Edgewise Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is EWTX moving today?
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for EWTX.
EWTX insider activity
Edgewise Therapeutics, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for EWTX.
EWTX contract awards, year to date.
Public federal awards linked to this ticker.
EWTX lobbying filings, year to date.
Registered lobbying filings matched to Edgewise Therapeutics, Inc. Common Stock.